Sanofi-Aventis (ADR) (SNY)

NetscribePhrmtcl (94.54) Submitted: 1/18/07 12:58 AM : Start Price: $43.23 SNY Score: -6.26

Sanofi-Aventis, ranks the world’s third largest pharmaceutical companies in the world, engages in the research, development, manufacture, and marketing of pharmaceutical products and human vaccines worldwide. The company specializes in allergy, cardi...

Report this Post Replies: 1 | Reply | Permalink

awolfson1015 (< 20) Submitted: 6/20/07 4:21 PM : Start Price: $40.48 SNY Score: 4.91

Quick background on the company: SNY is a French pharma company that operates all over the world and has a few well-known drugs. The idea behind this one is simple. SNY just dropped precipitously because the FDA denied approval for its fat loss dru...

Report this Post Replies: 1 | Reply | Permalink

reddingrunner (94.62) Submitted: 8/06/07 2:21 PM : Start Price: $39.87 SNY Score: 1.65

Ketterer sold me on this one too (along with HBC):

"a rich pipeline of 65 potential drugs should ensure strong earnings growth in coming years. Meanwhile, says Ketterer, the company should generate a staggering $55 billion in free cash flo...

Report this Post Replies: 0 | Reply | Permalink

frankp102 (< 20) Submitted: 8/24/06 8:50 PM : Start Price: $41.79 SNY Score: -12.25

SNY has new drug (rimonabant) in a new class of drugs (endocannabinoid receptor antagonist) which is effective in weight loss, metabolic syndrome, raises HDL (good cholesterol) an helps quit smoking. This drug has been approved in Europe and UK thi...

Report this Post Replies: 0 | Reply | Permalink

Kingswan23 (20.34) Submitted: 9/15/06 12:46 AM : Start Price: $40.61 SNY Score: -8.13

This company is unbelievable, if you read about their research technique, basically these guys are throwing together as many different possible drugs as possible and putting them in for approval. This compnay will be MAJOR in the longterm.

Report this Post Replies: 0 | Reply | Permalink

blcourtney (84.70) Submitted: 6/26/07 4:35 AM : Start Price: $39.01 SNY Score: 6.95

French drug giant at bottom of 52-wk range. Stroke drug Lovenox top seller, insulin brand Lantus rapid sales, popular Ambien for insomnia, and diet drug Acomplia likley FDA approval, plus $100MM US grant for bird flu vaccines.

Report this Post Replies: 0 | Reply | Permalink

Andymikester (< 20) Submitted: 2/03/07 2:07 PM : Start Price: $41.29 SNY Score: -1.39

Like their ratios, undervalued right now. Could possibly acquire Bristol-Squibb and become #1 in their sector worldwide. Also good for international diversity.

Report this Post Replies: 0 | Reply | Permalink

NuvoRiche (81.23) Submitted: 1/31/07 11:15 PM : Start Price: $41.02 SNY Score: -1.15

Several unique-in-class blockbusters with more in the pipeline. They are really swinging for the fences with their strategic thinking.

Report this Post Replies: 0 | Reply | Permalink

Gtrinvestor (99.98) Submitted: 4/17/08 12:29 PM : Start Price: $36.51 SNY Score: 4.26

It seems that all that matters to people any more is access to the best in health care. I'm guessing that this is only going to become more of an issue w/ the again US population, and the growing overseas wealth.





Everyone ...

Report this Post Replies: 0 | Reply | Permalink

donhaupt1 (56.31) Submitted: 12/27/06 6:55 PM : Start Price: $43.38 SNY Score: -7.02

Very promising diet drug (Acomplia {rimonabant)) with few side effects and good efficacy shown in 2 year trials published in JAMA and NEJM. Already approved in Europe, awaits FDA approval here possibly as soon as first quarter 2007. Not only did subj...

Report this Post Replies: 0 | Reply | Permalink